ArticlePloS one2008
Bradykinin [corrected] B1 receptor antagonism is beneficial in renal ischemia-reperfusion injury.
Article in PloS one, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 38 citations in OpenAlex.
- Kallikrein-kinin system as a potential target for the treatment of intervertebral disc degeneration.European journal of medical research · 2025Review
- Review
- COVID-19 cytokine storm: The anger of inflammation.Cytokine · 2020Review
- Kinin B1 receptor: a potential therapeutic target in sepsis-induced vascular hyperpermeability.Journal of translational medicine · 2020Article
- Kinin B1 Receptor Is Important in the Pathogenesis of Myeloperoxidase-Specific ANCA GN.Journal of the American Society of Nephrology : JASN · 2020Article
- Malaria infection promotes a selective expression of kinin receptors in murine liver.Malaria journal · 2019Article
- Renal and vascular effects of kallikrein inhibition in a model of Lonomia obliqua venom-induced acute kidney injury.PLoS neglected tropical diseases · 2019Article
- Bradykinin 1 receptor blockade subdues systemic autoimmunity, renal inflammation, and blood pressure in murine lupus nephritis.Arthritis research & therapy · 2019Article
- Carbon monoxide protects the kidney through the central circadian clock and CD39.Proceedings of the National Academy of Sciences of the United States of America · 2018Article
- MATE-1 modulation by kinin B1 receptor enhances cisplatin efflux from renal cells.Molecular and cellular biochemistry · 2017Article
- AS-IV protects against kidney IRI through inhibition of NF-κB activity and PUMA upregulation.International journal of clinical and experimental medicine · 2015Article
- Kinin B2 receptor does not exert renoprotective effects on mice with glycerol-induced rhabdomyolysis.World journal of nephrology · 2014Article
- Balance between the two kinin receptors in the progression of experimental focal and segmental glomerulosclerosis in mice.Disease models & mechanisms · 2014Article
- Kinin B1 receptor deficiency attenuates cisplatin-induced acute kidney injury by modulating immune cell migration.Journal of molecular medicine (Berlin, Germany) · 2014Article
- Altered glucose homeostasis and hepatic function in obese mice deficient for both kinin receptor genes.PloS one · 2012Article
- Article
- Transcriptome analysis of renal ischemia/reperfusion injury and its modulation by ischemic pre-conditioning or hemin treatment.PloS one · 2012Article
- Differential regulation of inducible and endothelial nitric oxide synthase by kinin B1 and B2 receptors.Neuropeptides · 2010Review
Corrections and comments
- Erratum issued
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Previously we have demonstrated that bradykinin B1 receptor deficient mice (B1KO) were protected against renal ischemia and reperfusion injury (IRI). Here, we aimed to analyze the effect of B1 antagonism on renal IRI and to study whether B1R knockout or antagonism could modulate the renal expression of pro and anti-inflammatory molecules. To this end, mice were subjected to 45 minutes ischemia and reperfused at 4, 24, 48 and 120 hours. Wild-type mice were treated intra-peritoneally with antagonists of either B1 (R-954, 200 microg/kg) or B2 receptor (HOE140, 200 microg/kg) 30 minutes prior to ischemia. Blood samples were collected to ascertain serum creatinine level, and kidneys were harvested for gene transcript analyses by real-time PCR. Herein, B1R antagonism (R-954) was able to decrease serum creatinine levels, whereas B2R antagonism had no effect. The protection seen under B1R deletion or antagonism was associated with an increased expression of GATA-3, IL-4 and IL-10 and a decreased T-bet and IL-1beta transcription. Moreover, treatment with R-954 resulted in lower MCP-1, and higher HO-1 expression. Our results demonstrated that bradykinin B1R antagonism is beneficial in renal IRI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.